An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus

Current Opinion in Endocrinology, Diabetes and Obesity - Tập 24 Số 1 - Trang 73-79 - 2017
Daniel S. Hsia1, Owen Grove, William T. Cefalu
1Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA

Tóm tắt

Purpose of review Sodium-glucose co-transporter-2 (SGLT2) inhibitors are the newest class of oral antihyperglycemic agents that have been approved for the treatment of diabetes mellitus. Over the past year, there have been significant developments in both the safety and efficacy of this class of medications that are presented in this review. Recent findings Apart from data on the glucose-lowering effect of SGLT2 inhibitors, other metabolic benefits have been demonstrated for this class of medications. Moreover, there have been three Food and Drug Administration Drug Safety Communications issued in 2015 that have led to additional drug labeling. The basic mechanism of action, indications, glucose-lowering benefits, other metabolic benefits, and adverse side-effects of SGLT2 inhibitors are presented in this review. Summary SGLT2 inhibitors are medications that have a unique mechanism of action and that lower glucose independent of insulin. Given the recent findings on efficacy and benefits, these agents are rapidly establishing their role in the treatment of diabetes. Especially in patients with type 2 diabetes not willing or not ready to start insulin, SGLT2 inhibitors may be another option in those patients requiring additional glucose lowering and in those with acceptable risk factor profiles. Although there appears to be some positive benefits in cardiovascular endpoints, more research on the long-term outcomes in people taking SGLT2 inhibitors is warranted.

Từ khóa


Tài liệu tham khảo

Menke, 2015, Prevalence of and trends in diabetes among adults in the United States, 1988–2012, JAMA, 314, 1021, 10.1001/jama.2015.10029

Ehrenkranz, 2005, Phlorizin: a review, Diab/Metab Res Rev, 21, 31, 10.1002/dmrr.532

Mudaliar, 2014, Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin, Diab Technol Therap, 16, 137, 10.1089/dia.2013.0167

Scheen, 2015, Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus, Drugs, 75, 33, 10.1007/s40265-014-0337-y

Shubrook, 2015, Empagliflozin in the treatment of type 2 diabetes: evidence to date, Drug Des Dev Ther, 9, 5793, 10.2147/DDDT.S69926

Triplitt, 2015, Canagliflozin treatment in patients with type 2 diabetes mellitus. Clinical medicine insights, Endocrinol Diabet, 8, 73

Fioretto, 2015, Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus, Cardiovasc Diabetol, 14, 142, 10.1186/s12933-015-0297-x

Moses, 2014, SGLT2 inhibitors: new medicines for addressing unmet needs in type 2 diabetes, Australas Med J, 7, 405, 10.4066/AMJ.2014.2181

Desouza, 2015, Cardiometabolic effects of a new class of antidiabetic agents, Clin Ther, 37, 1178, 10.1016/j.clinthera.2015.02.016

Santer, 2003, Molecular analysis of the SGLT2 gene in patients with renal glucosuria, J Am Soc Nephrol, 14, 2873, 10.1097/01.ASN.0000092790.89332.D2

Monami, 2014, Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials, Diabetes Obes Metab, 16, 457, 10.1111/dom.12244

Leiter, 2015, Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study, Diabetes Care, 38, 355, 10.2337/dc13-2762

Matthaei, 2015, Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial, Diabetes Care, 38, 365, 10.2337/dc14-0666

Rosenstock, 2015, Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial, Diabetes Obes Metab, 17, 936, 10.1111/dom.12503

Neal, 2015, Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes, Diabetes Care, 38, 403, 10.2337/dc14-1237

Cefalu, 2015, Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes, Diabetologia, 58, 1183, 10.1007/s00125-015-3547-2

Cefalu, 2015, Dapagliflozin's effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension, Diabetes Care, 38, 1218, 10.2337/dc14-0315

Zinman, 2015, Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes, N Engl J Med, 373, 2117, 10.1056/NEJMoa1504720

Majewski, 2015, Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes, Diabetes Care, 38, 429, 10.2337/dc14-1596

Sonesson, 2016, Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis, Cardiovasc Diabetol, 15, 37, 10.1186/s12933-016-0356-y

Rosenstock, 2015, Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors, Diabetes Care, 38, 1638, 10.2337/dc15-1380

Peters, 2015, Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition, Diabetes Care, 38, 1687, 10.2337/dc15-0843

Chowdhary, 2015, Canagliflozin-induced pancreatitis: a rare side effect of a new drug, Ther Clin Risk Manag, 11, 991, 10.2147/TCRM.S86641

Srivali, 2015, Acute pancreatitis in the use of canagliflozin: a rare side-effect of the novel therapy for type 2 diabetes mellitus, J Basic Clin Pharm, 6, 101, 10.4103/0976-0105.160753

Erondu, 2015, Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program, Diabetes Care, 38, 1680, 10.2337/dc15-1251

Bilezikian, 2016, Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin, J Clin Endocrinol Metab, 101, 44, 10.1210/jc.2015-1860

Thông tin
Thông tin xuất bản

Current Opinion in Endocrinology, Diabetes and Obesity

Tập 24 Số 1

73-79

Thông tin tác giả